Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 13/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19068207 | 0.99 | NTRK1 (0.53) | NTRK1PIK3CASLC2A1MAPK1PIM1 | |
| SCHEMBL31235685 | 0.89 | MAPK1 (0.59) | NTRK1PIK3CAMAPK1PIM1PIM3 | |
| SCHEMBL19351251 | 0.88 | AXL (0.61) | NTRK1KITAXLCDK8TNIK | |
| SCHEMBL19068211 | 0.87 | AXL (0.59) | NTRK1KITAXLCDK8TNIK | |
| SCHEMBL19351228 | 0.86 | DYRK1A (0.59) | NTRK1PIK3CAMAPK1PIM1PIM3 | |
| SCHEMBL19068206 | 0.85 | ROCK2 (0.61) | NTRK1PIK3CAMAPK1PIM1PIM3 | |
| SCHEMBL17951910 | 0.82 | NTRK1 (0.47) | NTRK1PIK3CASLC2A1MAPK1PIK3CG | |
| SCHEMBL17951905 | 0.81 | NTRK1 (0.48) | NTRK1PIK3CASLC2A1MAPK1KIT | |
| SCHEMBL17939337 | 0.78 | NTRK1 (0.46) | NTRK1PIK3CASLC2A1MAPK1PIK3CG | |
| SCHEMBL17939340 | 0.78 | NTRK1 (0.46) | NTRK1PIK3CASLC2A1MAPK1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9695200-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | NTRK1 2003/4885PIK3CA 873/4885SLC2A1 4224/4885 |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | NTRK1 2003/4885PIK3CA 873/4885SLC2A1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.